Shares of Ligand Pharmaceuticals Incorporated (LGND) are moving up about 7 percent on Tuesday morning trading after its partner Travere Therapeutics, Inc. received approval from the U.S. Food and Drug Administration for FILSPARI to reduce proteinuria.
The company's shares are currently trading at $230.32 on the Nasdaq, up 7.87 percent. The stock opened at $220.00 and has climbed as high as $230.51 so far in today's session. Over the past year, it has traded in a range of $98.89 to $230.51.
The approval comes as Travere's Phase 3 DUPLEX Study, the largest head-to-head interventional study in FSGS to date, showed that patients treated with FILSPARI in the overall study population experienced a statistically significant 46% reduction in proteinuria from baseline to Week 108 compared to 30% for those treated with maximum labeled dose irbesartan.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.